Peter D Senter

Dr. Peter D Senter


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 June 2009 in Current Opinion in Chemical Biology
Verified
Journal Article
Closed access
PSPeter D Senter
Peter D Senter

14 March 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NONicole M. Okeley
Nicole M. Okeley
SAStephen C. Alley
Stephen C. Alley
MAMartha E. Anderson
Martha E. Anderson
TBTamar E. Boursalian
Tamar E. Boursalian
PBPatrick J. Burke
Patrick J. Burke
PSPeter D Senter
Peter D Senter
The key role played by fucose in glycoprotein and cellular function has prompted significant research toward identifying recombinant and biochemical strategies for blocking its incorporation into proteins and membrane structures. Technologies surrounding engineered cell lines have evolved for the inhibition of in vitro fucosylation, but they are not applicable for in vivo use and drug development. To address this, we screened a panel of fucose analogues and identified 2-fluorofucose and 5-alkynylfucose derivatives that depleted cells of GDP-fucose, the substrate used by fucosyltransferases to incorporate fucose into protein and cellular glycans. The inhibitors were used in vitro to generate fucose-deficient antibodies with enhanced antibody-dependent cellular cytotoxicity activities. When given orally to mice, 2-fluorofucose inhibited fucosylation of endogenously produced antibodies, tumor xenograft membranes, and neutrophil adhesion glycans. We show that oral 2-fluorofucose treatment afforded complete protection from tumor engraftment in a syngeneic tumor vaccine model, inhibited neutrophil extravasation, and delayed the outgrowth of tumor xenografts in immune-deficient mice. The results point to several potential therapeutic applications for molecules that selectively block the endogenous generation of fucosylated glycan structures.

1 December 2001 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
PSPeter D Senter
Peter D Senter
CSCaroline J Springer
Caroline J Springer

23 October 2001 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
PSPeter D Senter
Peter D Senter
KBKevin S. Beam
Kevin S. Beam
BMBruce Mixan
Bruce Mixan
AWAlan F. Wahl
Alan F. Wahl

1 July 2011 in mAbs
Verified
Journal Article
Open access
ABAlain Beck
Alain Beck
PSPeter D Senter
Peter D Senter
RCRavi J. Chari
Ravi J. Chari
The World Antibody Drug Conjugate Summit Europe, organized by Biorbis/ Hanson Wade was held in Frankfurt, Germany on February 21-23, 2011. Antibody drug conjugates (ADCs), also called immunoconjugates, are becoming an increasingly important class of therapeutics as demonstrated by the attendance of nearly 100 delegates at this highly focused meeting. Updates on three ADCs that are in late-stage clinical development, trastuzumab emtansine (T-DM1), brentuximab vedotin (SGN-35) and inotuzumab ozogamicin (CMC-544), were presented by speakers from ImmunoGen, Genentech, Roche, Seattle Genetics and Pfizer. These ADCs have shown encouraging therapeutic effects against solid tumors (T-DM1) and hematological malignancies (SGN-35, CMC-544). The key feature of the new generation of ADCs is the effective combination of the cytotoxicity of natural or synthetic highly potent antineoplastic agents, tumor selective monoclonal antibodies and blood-stable optimized linkers. Early clinical data for ADCs were showcased by Progenics Pharmaceuticals (PSMA ADC), Celldex (CDX-011) and Biotest (BT-062). Takeda, MedImmune and sanofi-aventis outlined their strategies for process development and analytical characterization. In addition, presentations on duocarmycin based-ADCs, alpha emitting immunoconjugates and antibody-conjugated nanoparticles were given by representatives from Syntarga, Algeta and the University of Stuttgart, respectively. For more information, please visit http://www.adc-summit.com.